the M.D. Anderson Endowed Professor of Department of Biology and Biochemistry at University of Huston, and the Director of Center for Nuclear Receptors and Cell Signaling.
Professor Zhang is a well-known expert in the field of oncovirus research, focusing on the research of the oncolytic HSV. He has published 60+ articles and obtained 12+ patents. Besides, Professor Zhang is committed to translational research to develop cancer therapeutics. The patented intellectual properties generated by the lab have led to the formation of two biotech companies that are devoted to translating the research from the lab into clinical application, with products currently in the stage of clinical trials.
Postdoctoral Fellow in Laboratory of Molecular Biology, Institut Curie (France)，and Ph.D. in medical research from Kyoto University (Japan), where she published her doctoral thesis as the first author in Cancer Research, an authoritative journal of basic research in oncology.
She is experienced in basic cancer research and R& D of cancer drugs. In 1994, she entered in French pharmaceutical enterprises. She formerly served as director of ant-tumor drug R&D in French Etypharm, Senior cancer consultant in headquarter of Sanofi (China), a global pharmaceutical giant, minister of the anti-tumor drug R&D in French AB Science, senior advisor of anti-tumor drug R&D in Shanghai Sunway Biotech CO., LTD, Chief Medical Officer of Clinical Phase I/II Trial in Cancer Research Center(Paris, France), and vice president in French ImmuPharma. She used to be responsible for preclinical testing (animal effectiveness and toxicity testing) and phase I/II clinical trials of oral, intravenous, and local injections of anti-tumor molecules (small molecule chemicals and targeting molecules), including five first in human trials (FIH).